Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408-2417. Abstract
Deininger M, O'Brien SG, Guilhot F, et al. International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood. 2009;114:462. Abstract 1126.
Cortes JE, Baccarani M, Guilhot F, et al. Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. J Clin Oncol. 2010;28:424-430. Abstract
Hehlmann R, Lauseker M, Jung-Munkwitz S, et al. Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon- in newly diagnosed chronic myeloid leukemia. J Clin Oncol. 2011;29:1634-1642. Abstract
Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010;362:2260-2270. Abstract
Kantarjian HM, Shah NP, Cortes JE, et al. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2- year follow-up from a randomized phase 3 trial (DASISION). Blood. 2012;119:1123-1129. Abstract
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Chronic myelogenous leukemia. Version 3.2013.
Saglio G, Kim DW, Issaragrisil S, et al; for the ENESTnd Investigators. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362:2251-2259. Abstract
Ibrahim AR, Eliasson L, Apperley JF, et al. Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy. Blood. 2011;117:3733-3736. Abstract
Noens L, van Lierde MA, De Bock R, et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood. 2009;113:5401-5411. Abstract
Marin D, Bazeos A, Mahon FX, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol. 2010;28:2381-2388. Abstract
Larson RA, Hochhaus A, Hughes TP, et al. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome- positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia. 2012;26:2197-2203. Abstract
Mahon FX, Réa D, Guilhot J, et al; on behalf of the Intergroupe Français des Leucémies Myéloïdes Chroniques (FILMC). Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010;11:1029-1035. Abstract
Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487-497. Abstract
Cortes JE, Kantarjian HM, Brümmendorf TH, et al. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood. 2011;118:4567-4576. Abstract
Cortes JE, Kim DW, Pinilla-Ibarz J, et al. PACE: a pivotal phase II trial of ponatinib in patients with CML and Ph+ALL resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation. J Clin Oncol. 2012;30. Abstract 6503.
Nicolini FE, Lipton JH, Kantarjian H, et al. Subcutaneous omacetaxine mepesuccinate in patients with chronic phase (CP) or accelerated phase (AP) chronic myeloid leukemia (CML) resistant/intolerant to two or three approved tyrosine-kinase inhibitors (TKIs). J Clin Oncol. 2012;30. Abstract 6513.
Partridge AH, LaFountain A, Mayer E, Taylor BS, Winer E, Asnis-Alibozek A. Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol. 2008;26:556-562. Abstract

CE

The Nurse View: Common Clinical Challenges and Best Practices in Chronic Myeloid Leukemia

Authors: Sandra Allen-Bard, BSN, MSN, NPC, ANCC, AOCNP; Patricia S. Ault, FNP-BC, DNP; Stephanie Bauer, BSN, MSN, FNP; Mary Beth Rios, RN
CE Released: 2/8/2013
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 2/8/2014

Target Audience and Goal Statement

This activity is intended for oncology nurses and other healthcare professionals who treat patients with chronic myeloid leukemia (CML).

The goal of this activity is to discuss the optimal approaches to treating patients with CML, including strategies for choosing treatment, monitoring responses, and optimizing adherence.

Upon completion of this activity, participants will be able to:

Outline recommended treatment approaches for patients with newly diagnosed, relapsed/refractory, or resistant CML
Describe the nurse’s role in monitoring for disease response and relapse
Apply the most current nursing interventions for optimizing adherence to oral therapies, for mitigating common side effects of treatment, and for discussing these approaches with patients to improve adherence and address side effects

Disclosures

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

Moderator

Sandra Allen-Bard, BSN, MSN, NPC, ANCC, AOCNP

Leukemia Nurse Practitioner, Weill Cornell Medical College/New York-Presbyterian Hospital, New York, New York

Disclosures

Disclosure: Sandra Allen-Bard, BSN, MSN, NPC, ANCC, AOCNP has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Novartis Pharmaceuticals Corporation; Celgene Corporation; Bristol-Myers Squibb Company
Served as a speaker or a member of a speakers bureau for: Novartis Pharmaceuticals Corporation; Celgene Corporation; Bristol-Myers Squibb Company

Ms Allen-Bard does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Ms Allen-Bard does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Panelists

Patricia S. Ault, FNP-BC, DNP

Family Nurse Practitioner, MD Anderson Cancer Center, Houston, Texas

Disclosures

Disclosure: Patricia S. Ault, FNP-BC, DNP has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Novartis Pharmaceuticals Corporation; Bristol-Myers Squibb Company
Served as a speaker or a member of a speakers bureau for: Bristol-Myers Squibb Company; Novartis Pharmaceuticals Corporation; Otsuka Pharmaceutical Co., Ltd.

Dr Ault does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Ault does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Stephanie Bauer, BSN, MSN, FNP

Nurse Practitioner, Washington University School of Medicine, St Louis, Missouri

Disclosures

Disclosure: Stephanie Bauer, BSN, MSN, FNP has disclosed the following relevant financial relationships:
Served as a speaker or a member of a speakers bureau for: Novartis Pharmaceuticals Corporation; ARIAD Pharmaceuticals, Inc.; Celgene Corporation; Sanofi

Ms Bauer does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Ms Bauer does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Mary Beth Rios, RN

Research Nurse Manager, Department of Leukemia, MD Anderson Cancer Center, Houston, Texas

Disclosures

Disclosure: Mary Beth Rios, RN has disclosed the following relevant financial relationships:
Owns stock, stock options, or bonds from: Photoimmune Biotechnology

Ms Rios does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Ms Rios does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Editors

Charlotte Warren

Scientific Director, Medscape, LLC

Disclosures

Disclosure: Charlotte Warren has disclosed no relevant financial relationships.

Carol Cadmus

Senior Clinical Editor, Medscape, LLC

Disclosures

Disclosure: Carol Cadmus has disclosed no relevant financial relationships.

CE Reviewer

Nafeez Zawahir, MD

CME Clinical Director, Medscape, LLC

Disclosures

Disclosure: Nafeez Zawahir, MD, has disclosed no relevant financial relationships.

Nurse Planner

Laurie E. Scudder, DNP, NP

Nurse Planner, Continuing Professional Education Department, Medscape, LLC; Clinical Assistant Professor, School of Nursing and Allied Health, George Washington University, Washington, DC

Disclosures

Disclosure: Laurie E. Scudder, DNP, NP, has disclosed no relevant financial relationships.

Accreditation Statements

For Nurses

Medscape, LLC is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

Awarded 0.75 contact hour(s) of continuing nursing education for RNs and APNs; 0.75 contact hours are in the area of pharmacology.

Accreditation of this program does not imply endorsement by either Medscape, LLC or ANCC.

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

Read the target audience, learning objectives, and author disclosures.
Study the educational content online or printed out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

The Nurse View: A Clinical Resource for Oncology Nurses

From Medscape Education Oncology

The Nurse View: Common Clinical Challenges and Best Practices in Chronic Myeloid Leukemia

Authors: Sandra Allen-Bard, BSN, MSN, NPC, ANCC, AOCNP; Patricia S. Ault, FNP-BC, DNP; Stephanie Bauer, BSN, MSN, FNP; Mary Beth Rios, RNFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED FOR CREDIT

CE Released: 2/8/2013

Valid for credit through: 2/8/2014

processing....

Abbreviations

AE = adverse event
CCyR = complete cytogenetic response
CML = chronic myeloid leukemia
ECG = electrocardiogram
EFS = event-free survival
FDA = Food and Drug Administration
FISH = fluorescence in situ hybridization
GI = gastrointestinal
HSCT = hematopoietic stem cell transplant
MMR = major molecular response
NCCN = National Comprehensive Cancer Network
OS = overall survival
PCR = polymerase chain reaction
Ph+ = Philadelphia chromosome positive
RT-PCR = real-time polymerase chain reaction
TKI = tyrosine kinase inhibitor

« Return to: The Nurse View: Common Clinical Challenges and Best Practices in Chronic Myeloid Leukemia

CE Information Download Slides

Resources

Print
Like Tweet

References

Faculty and Disclosures

Moderator

Sandra Allen-Bard, BSN, MSN, NPC, ANCC, AOCNP

Panelists

Patricia S. Ault, FNP-BC, DNP

Stephanie Bauer, BSN, MSN, FNP

Mary Beth Rios, RN

Editors

Charlotte Warren

Carol Cadmus

CE Reviewer

Nafeez Zawahir, MD

Nurse Planner

Laurie E. Scudder, DNP, NP

CE

The Nurse View: Common Clinical Challenges and Best Practices in Chronic Myeloid Leukemia

Target Audience and Goal Statement

Disclosures

Moderator

Sandra Allen-Bard, BSN, MSN, NPC, ANCC, AOCNP

Panelists

Patricia S. Ault, FNP-BC, DNP

Stephanie Bauer, BSN, MSN, FNP

Mary Beth Rios, RN

Editors

Charlotte Warren

Carol Cadmus

CE Reviewer

Nafeez Zawahir, MD

Nurse Planner

Laurie E. Scudder, DNP, NP

Accreditation Statements

For Nurses

Instructions for Participation and Credit

The Nurse View: Common Clinical Challenges and Best Practices in Chronic Myeloid Leukemia

Abbreviations